by MM360 Staff | Apr 25, 2025 | Uncategorized
Source: CureToday articles In advanced head and neck squamous cell carcinoma, evorpacept and Keytruda didn’t meet the primary endpoints of the ASPEN-03 and ASPEN trials. Read More
by MM360 Staff | Apr 25, 2025 | Uncategorized
Source: CureToday articles Among patients with oncogene-driven advanced NSCLC who were treated with TKIs, ctDNA clearance was associated with improved survival end points. Read More
by MM360 Staff | Apr 24, 2025 | Uncategorized
Source: CureToday articles Kathleen Coughlin, although small in stature, is often referred to as the “Bulldozer.” Read More
by MM360 Staff | Apr 24, 2025 | Uncategorized
Source: CureToday articles CURE spoke with John Crispino, the director of the division of experimental hematology at St. Jude Children’s Research Hospital. Read More
by MM360 Staff | Apr 24, 2025 | Uncategorized
Source: CureToday articles The first patient has been enrolled in the ARID II trial evaluating Voro Urologic Scaffold to improve continence after prostate cancer surgery. Read More
by MM360 Staff | Apr 24, 2025 | Uncategorized
Source: CureToday articles After a long battle with illness and seeking many specialists, I emphasize the need to self-advocate for ongoing care following my cancer diagnosis. Read More